Report Reserve announces addition of Clinical Trial Recruitment Strategies in Oncology Report
GBI Research, the leading business intelligence provider, has released its latest research, "Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems Will Reduce Recruitment Time and Cost", which provides insights into recruitment strategies, challenges and solutions for on-time recruitment in oncology trials.
- (1888PressRelease) May 12, 2011 - Report Reserve announces addition of Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost Report. To access this report please visit http://www.reportreserve.com/reportdet.php?company=GBI%20Research&reportid=28811
GBI Research, the leading business intelligence provider, has released its latest research, "Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems Will Reduce Recruitment Time and Cost", which provides insights into recruitment strategies, challenges and solutions for on-time recruitment in oncology trials. The report also examines case studies to illustrate enhanced recruitment in a shorter time. The report provides an in-depth analysis of the trials conducted by major pharmaceutical companies for the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and brain cancer.
Increasing Focus of Major Pharmaceutical Companies on Oncology Markets
Major pharmaceutical companies conduct clinical trials in many therapeutic areas, such as cardiovascular diseases, infectious diseases, oncology, metabolic disorders and central nervous system disorders.
GBI Research's analysis finds that oncology is responsible for the most trials across the globe. The major pharmaceutical companies conducted more clinical trials in oncology than in other therapy areas during the period between 2005 and 2010.
The figure below shows the number of trials by major pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Roche, Merck and Sanofi Aventis, and clearly demonstrates the prevalence of oncology trials.
Clinical Trial Recruitment Strategies in Oncology, Global, Clinical Trials by Major Pharmaceutical Companies, 2005-2010
Source: GBI Research, www.clinicaltrials.gov, Company Websites
Pharmaceutical companies are doing extensive research in oncology trials compared to other therapeutic areas. The higher incidence rates in cancer and increase in severity are the major drivers.
GBI Research's analysis estimated that the cost of one trial is approximately $2.28m. As the average time of an oncology trial is 4.5 years, the average cost of a trial is $0.5m per year.
Outsourcing Clinical Trial Patient Recruitment Will Help Companies to Save Cost and Time
Outsourcing of clinical trials to clinical research organizations (CROs) is becoming a major trend for pharmaceutical companies to reduce the time and cost of a trial. Outsourcing can be done for the whole trial or for part of a trial, which can be the start-up Phase, the ongoing part of the trial, or the data management part of the trial.
Outsourcing a part of the trial helps with time management and relieves the sponsor to allow them to plan better for the other important parts of the trial, which then permits those to be managed in a better way.
There are many CROs who work actively for patient recruitment. They manage their own online database of investigators, as well as the hospitals, clinics and private physicians and professionally active physicians. They have an idea about the type of patients to be obtained and about the kind and number of patients the site can provide for. Examples of CROs are D. Anderson and Company, Max Neeman, Clinlogix, PPD, and Quintiles.
Clinical Trial Recruitment Strategies in Oncology, Outsourcing Strategy, 2005-2010
Source: GBI Research
Increasing Use of IT-Enabled Patient Recruitment Platforms Will Help in Better Recruitment Management
GBI Research finds that pharmaceutical companies are increasingly adopting e-clinical trial solutions in the drug development phase. The economic downturn, increased competition, patent expiry and the drying up of pipelines are pressurizing the biopharmaceutical industry to adopt e-clinical trial solutions and services that could optimize the drug development process and cut down costs.
Online recruitment could be made better by the use of electronic medical records. The electronic repositories of the patients' database could be of great help at the time of recruitment.
A new study held at the University of Cincinnati (UC) shows that by using electronic medical records as a tool for patient recruitment, the number of volunteers participating in the trial can be increased, along with the increase in referrals from physicians from the referral community.
The success of a clinical trial totally depends on the recruitment of eligible candidates within the timelines. In the field of oncology, only 2% of the patients participate even though the researchers spend a lot of time in planning for the timely recruitment.
The electronic health record (EHR) is an electronic health document of patients including the information related to patients' demographics, progress notes, and medications, vital signs, past medical history, lab data and radiology reports. It has an inherent ability to bring together data from multiple practice sites under one electronic system, which enables quick development of a huge resource of patients' records. An example of this is Holston Medical Group's (HMG) EHR database, which with 200,000 patient records is an invaluable resource in prospectively assessing the actual number of patients that may meet trial protocols. These kinds of health records allow coverage of a wide range of patients from a large geographic area for a trial.
There are many reasons for lower rates of participation in cancer trials. The physician who enrolls the patients for trials and the patients who agree to be part of the trial both have a barrier for participation in the trial. Overcoming these obstacles by a proper recruitment plan is the only way to bring an effective therapeutic to the market.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam